瑞普生物股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本次股东会召开的基本情况 1、股东会届次：2026年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创 业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章 程》的有关规定。 4、会议时间： 证券代码：300119 证券简称：瑞普生物 公告编号：2026-003 （1）现场会议时间：2026 年 3 月 3 日（星期二）14:30 （2）网络投票时间为：通过深圳证券交易所系统进行网络投票的具体时间 为 2026 年 3 月 3 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为 2026 年 3 月 3 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 （1）现场投票：包括本人出席及 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2026-001 瑞普生物股份有限公司 第六届董事会第二次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 1 产业基金暨关联交易的公告》。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 关联董事李守军、李睿在审议本议案时回避表决。 本议案已经公司第六届董事会战略委员会第一次会议及独立董事 2026 年第 一次专门会议审议通过，尚需提交公司 2026 年第一次临时股东会审议。 2、审议通过了《关于召开 2026 年第一次临时股东会的议案》 瑞普生物股份有限公司（以下简称"公司"）第六届董事会第二次（临时） 会议于 2026 年 2 月 12 日在公司会议室以现场结合通讯表决方式召开。会议通知 于 2026 年 2 月 9 日以书面及电子邮件等方式送达全体董事。公司应出席董事 9 人，实际出席董事 9 人（其中：独立董事王凯以通讯方式参会），参与表决董事 9 人。本次会议由董事长李守军先生主持，公司高级管理人员列席了会议。本次 会议的召集、召开和表决程序符合 ...

格隆汇2月12日丨瑞普生物(300119.SZ)公布，为推进公司核心战略落地，拓展重点领域业务边界与行业 影响力，充分借助专业机构的资本与资源优势，瑞普生物股份有限公司于2026年2月12日与海通并购 （上海）私募基金管理有限公司（简称"海通并购资本"）、海通开元投资有限公司（简称"海通开元投 资"）、高邮市产业引导基金（有限合伙）（简称"高邮产业引导基金"）及关联方天津瑞晟私募基金管 理有限公司（简称"瑞晟私募"）签署《江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）之合伙协 议》，拟共同出资设立江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）（暂定名，以市场监督管 理机关核准的名称为准，简称"合伙企业"）。该合伙企业将聚焦动物保健、合成生物、宠物、生物医药 等重点领域开展产业投资。合伙企业认缴出资总额为人民币10亿元，其中，公司作为有限合伙人以自有 资金及自筹资金出资人民币2.95亿元，占合伙企业认缴出资总额的29.50%。 ...

格隆汇2月12日丨瑞普生物(300119.SZ)公布，为推进公司核心战略落地，拓展重点领域业务边界与行业 影响力，充分借助专业机构的资本与资源优势，瑞普生物股份有限公司于2026年2月12日与海通并购 （上海）私募基金管理有限公司（简称"海通并购资本"）、海通开元投资有限公司（简称"海通开元投 资"）、高邮市产业引导基金（有限合伙）（简称"高邮产业引导基金"）及关联方天津瑞晟私募基金管 理有限公司（简称"瑞晟私募"）签署《江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）之合伙协 议》，拟共同出资设立江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）（暂定名，以市场监督管 理机关核准的名称为准，简称"合伙企业"）。该合伙企业将聚焦动物保健、合成生物、宠物、生物医药 等重点领域开展产业投资。合伙企业认缴出资总额为人民币10亿元，其中，公司作为有限合伙人以自有 资金及自筹资金出资人民币2.95亿元，占合伙企业认缴出资总额的29.50%。 ...

作为未来产业之一，生物制造赛道近期多点开花、动能充沛。政策层面持续加码，上海市近期印发行动 方案，将生物制造纳入积极引导的新兴产业领域，确立其战略优先级；企业端积极发力，富祥药业 （300497）通过成立跨国合资公司推进微生物蛋白全球化布局；科研前沿同步突破，"合成高等生物"先 导项目启动，AI驱动下的生命科学创新持续深化，多方协同发力激活万亿产业新潜力。 ● 本报记者 傅苏颖 万亿赛道根基渐牢 近年来，政策高度聚焦产业化落地与技术突破，形成多层次支撑体系，促进我国生物制造产业蓬勃发 展。 工信部此前披露，"十四五"期间，我国生物制造产业规模稳步扩大，总规模达1.1万亿元，生物发酵产 品产量占全球70%以上。其中食品及添加剂、生物制药等细分领域年产值超4000亿元，推动生物制造成 为新的经济增长点。易凯资本预测，到2030年，中国生物制造市场规模将会接近1.8万亿元。 富祥药业同样聚焦微生物蛋白细分赛道。公司相关负责人对中国证券报记者表示，依托长期深耕高端抗 生素发酵领域的积累，公司拥有成熟的微生物发酵工艺、规模化生产能力及严格质控体系，微生物蛋白 项目在发酵调控、工艺放大等环节，与传统医药发酵业务具备显著技 ...

作为未来产业之一，生物制造赛道近期多点开花、动能充沛。政策层面持续加码，上海市近期印发行动 方案，将生物制造纳入积极引导的新兴产业领域，确立其战略优先级；企业端积极发力，富祥药业通过 成立跨国合资公司推进微生物蛋白全球化布局；科研前沿同步突破，"合成高等生物"先导项目启动，AI 驱动下的生命科学创新持续深化，多方协同发力激活万亿产业新潜力。 ● 本报记者 傅苏颖 万亿赛道根基渐牢 近年来，政策高度聚焦产业化落地与技术突破，形成多层次支撑体系，促进我国生物制造产业蓬勃发 展。 工信部此前披露，"十四五"期间，我国生物制造产业规模稳步扩大，总规模达1.1万亿元，生物发酵产 品产量占全球70%以上。其中食品及添加剂、生物制药等细分领域年产值超4000亿元，推动生物制造成 为新的经济增长点。易凯资本预测，到2030年，中国生物制造市场规模将会接近1.8万亿元。 长城证券化工新材料首席分析师肖亚平在接受中国证券报记者采访时表示，合成生物学技术作为生物制 造的核心支撑，可推动产业实现低碳生产、提升劳动生产率，其成果广泛应用于医疗健康、能源开发、 环境保护、工业制造等多个领域，为解决人类面临的各类发展挑战提供创新解决方案， ...

Core Viewpoint - The animal health sector experienced a rise of 1.15% on February 3, with *ST Green康 leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Individual Stock Performance - *ST Green康 (002868) closed at 36.70, with a gain of 3.29% and a trading volume of 11,000 lots, amounting to 39.61 million yuan [1]. - 回盛生物 (300871) closed at 28.30, up by 2.83%, with a trading volume of 166,400 lots and a turnover of 467 million yuan [1]. - 大禹生物 (920970) closed at 8.14, increasing by 2.13%, with a trading volume of 23,300 lots and a turnover of 18.92 million yuan [1]. - 普莱柯 (603566) closed at 14.00, up by 2.04%, with a trading volume of 66,100 lots and a turnover of 91.87 million yuan [1]. - 驱动力 (920275) closed at 9.15, increasing by 1.78%, with a trading volume of 14,900 lots and a turnover of 13.61 million yuan [1]. - 永顺生物 (920729) closed at 9.43, up by 1.73%, with a trading volume of 52,100 lots and a turnover of 48.48 million yuan [1]. - 科前生物 (688526) closed at 16.18, increasing by 1.25%, with a trading volume of 29,000 lots and a turnover of 46.60 million yuan [1]. - 申联生物 (688098) closed at 9.45, up by 0.96%, with a trading volume of 29,700 lots and a turnover of 27.90 million yuan [1]. - 生物股份 (600201) closed at 16.42, increasing by 0.86%, with a trading volume of 400,700 lots and a turnover of 655 million yuan [1]. - 瑞普生物 (300119) closed at 19.16, up by 0.63%, with a trading volume of 60,400 lots and a turnover of 115 million yuan [1]. Group 3: Capital Flow - The animal health sector saw a net outflow of 155 million yuan from institutional investors, while retail investors contributed a net inflow of 119 million yuan [2]. - The main capital flow data indicates that 中牧股份 (600195) had a net inflow of 5.91 million yuan from institutional investors [3]. - 普莱柯 (603566) experienced a net inflow of 5.90 million yuan from institutional investors, while retail investors had a net outflow of 12.09 million yuan [3]. - *ST Green康 (002868) had a net inflow of 2.82 million yuan from institutional investors, with retail investors contributing a net inflow of 2.25 million yuan [3].

Investment Rating - The report assigns an "Accumulate" rating for the industry [3] Core Insights - The price of piglets follows a clear historical pattern, with expectations for continued price increases followed by a decline around May/June. A significant capacity reduction cycle is anticipated in 2026, primarily occurring in the second half of the year, while stock prices are expected to start rising in the first half [5][6] - The report emphasizes that piglet prices are influenced by production patterns, with December and January being peak slaughter months, leading to increased demand for piglets. Conversely, supply remains relatively stable, which can lead to price increases when demand surges [7] - The report highlights that piglet prices do not correlate with pig price expectations and cannot be used to predict pig prices. The annual variations in piglet prices are consistent, while pig prices fluctuate yearly, indicating a lack of direct relationship [7] - The report recommends focusing on the pig farming sector, predicting a significant capacity reduction cycle in 2026. It suggests that the first half of 2026 will resemble the first half of 2023, with losses in fat pigs but profits in piglets, leading to a smoother capacity reduction after the anticipated price drop in May/June [7] - Key companies to watch include Muyuan Foods, Wens Foodstuff Group, Tiankang Biological, Juxing Agriculture, and Shennong Group, as their valuations are currently at the bottom, with potential for stock price increases as the industry faces losses and clearer capacity reduction trends [7][8] Summary by Sections Historical Price Trends - Piglet prices exhibit a clear historical trend, typically bottoming out in December/January and peaking in May/June. The fluctuations are tied to seasonal production patterns and demand cycles [5][7] Production and Supply Dynamics - The report discusses the relationship between supply and demand, noting that while supply is stable, demand spikes during certain months can lead to price increases. The cyclical nature of pig farming is highlighted, with adjustments made to align production with demand [7] Investment Opportunities - The report identifies a significant capacity reduction cycle in the pig farming industry for 2026, suggesting that investors should focus on companies with strong fundamentals and current low valuations, as they are likely to benefit from the anticipated market changes [7][8]

Core Viewpoint - The animal health sector experienced a slight decline of 0.23% on January 30, with Jinhe Biological leading the drop. The Shanghai Composite Index closed at 4117.95, down 0.96%, while the Shenzhen Component Index closed at 14205.89, down 0.66% [1]. Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Huisheng Biological rising by 3.51% to 29.46, while Jinhe Biological fell by 2.98% to 6.51 [1][2]. - The trading volume for Huisheng Biological was 303,100 shares, with a transaction value of 901 million yuan, indicating strong market interest [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 59.82 million yuan from institutional investors, while retail investors experienced a net outflow of 81.83 million yuan, indicating a shift in investor sentiment [2][3]. - Among individual stocks, Huisheng Biological attracted a significant net inflow of 1.23 billion yuan from institutional investors, while Jinhe Biological faced a net outflow of 543.32 million yuan [3].

格隆汇1月29日丨瑞普生物(300119.SZ)在投资者互动平台表示，公司目前无尼帕病毒相关的针对性疫 苗、药品，将持续关注相关病毒动态，合理评估研发机会。 ...